Slide 1: Solid Quarter driven by Strong Performance in Americas
Q4 Solid Quarter driven by Strong CellaVision Interim Report Performance in Americas Year-end Bulletin 2025 Organic sales growth: Q4, 2025: 12.2% (-7.4) EBITDA margin: Q4, 2025: 33% (33) Oktober 1st – December 31st, 2025 Net sales increased by 5.6% (-7.0) to SEK 197 m (187). Sales increased organica
Slide 2: CEO's Comment
CEO’s Comment CellaVision ended the year with a positive quarter mainly demand for our solutions, particularly from larger integrated customer site. It is designed to enhance the customer driven by strong regional performances in the Americas and health networks in the US. experience, unveiling a fu
Slide 3: Sales, Earnings and Investments
Sales, Earnings and Investments Net Sales and Currency Effects Operating Expenses Sales per quarter and rolling 12 months Net sales for the fourth quarter increased to SEK 197 m (187), Operating expenses for the fourth quarter decreased by 1 percent an increase of 6 percent compared to the correspon
Slide 4: Investments, Cash Flow, Parent Company
Investments Cash flow from investing activities for the quarter amounted CellaVision continuously capitalizes expenses related to to SEK -18 m (-24) and was, as in the corresponding period last product development. During the quarter, capitalized year, mainly related to capitalized expenses for rese
Slide 5: Development in the Geographical Markets
Development in the Geographical Markets Americas: SEK 90 m (60) EMEA: SEK 80 m (74) APAC: SEK 28 m (52) Sales in the Americas increased by 50 percent, reaching Sales in the EMEA region increased by 7 percent to SEK 80 m Sales in the APAC region amounted to SEK 28 m (52), SEK 90 m (60), compared to t
Slide 6: Research and Development
Research and Development Our vision is to elevate healthcare through validated at a selected customer site. Designed the evolution of microscopy. By devoting to elevate the customer experience, the considerable resources to research and Digital Cell Morphology Software introduces development, we con
Slide 7: Annual General Meeting
Annual General Meeting Annual General Meeting 2026 The Board of Directors proposes to the Annual General Meeting 2026 to increase the dividend to SEK 2.75 per share be paid for 2025 (2.50), which is in line with the company´s dividend policy. The CellaVision Annual General Meeting 2026 will be held
Slide 8: Income Statement in Summary and Consolidated Statement of Comprehensive Income, Group
Income Statement in Summary and Consolidated Statement of Comprehensive Income, Group Amounts in ‘ 000 SEK Note Oct-Dec 2025 Oct-Dec 2024 Jan-Dec 2025 Jan-Dec 2024 Net sales 4 197,205 186,688 758,968 723,217 Cost of goods sold -65,410 -57,517 -239,091 -236,143 Gross profit 131,795 129,171 519,877 48
Slide 9: Per Share Data, Quarterly Earnings Trend
Per Share Data Per share data Oct-Dec 2025 Oct-Dec 2024 Jan-Dec 2025 Jan-Dec 2024 Earnings per share, before and after dilution, SEK */ 1.79 1.72 6.42 5.90 Equity per share, SEK 37.21 34.20 37.21 34.20 Number of shares outstanding 23,851,547 23,851,547 23,851,547 23,851,547 Average number of shares
Slide 10: Balance Sheet in Summary, Group
Balance Sheet in Summary, Group Amounts in ' 000 SEK Note 12/31/2025 12/31/2024 Assets Intangible assets 5 528,877 487,645 Tangible assets 6 122,374 119,943 Financial assets 7 2,544 2,653 Inventory 111,808 124,823 Trade receivables 7 120,333 102,824 Other receivables 7 20,736 25,736 Cash and bank 7
Slide 11: Cash Flow Statement in Summary, Group
Cash Flow Statement in Summary, Group Amounts in ‘ 000 SEK Oct-Dec 2025 Oct-Dec 2024 Jan-Dec 2025 Jan-Dec 2024 Result before taxes 54,543 51,489 194,264 176,860 Adjustment for items not included in cash flow -1,558 15,681 40,837 63,144 Income tax paid -10,054 -6,877 -31,383 -26,154 Cash flow from op
Slide 12: Income Statement in Summary, Parent Company
Income Statement in Summary and Consolidated Statement of Comprehensive Income, Parent Company Amounts in ‘ 000 SEK Oct-Dec 2025 Oct-Dec 2024 Jan-Dec 2025 Jan-Dec 2024 Net sales 155,470 142,494 583,505 555,523 Cost of goods sold -39,032 -29,524 -138,243 -133,896 Gross profit 116,438 112,970 445,262
Slide 13: Balance Sheet in Summary, Parent Company
Balance Sheet in Summary, Parent Company Amounts in ‘ 000 SEK 12/31/2025 12/31/2024 Assets Intangible assets 23,953 26,944 Tangible assets 12,725 7,074 Deferred tax assets 532 755 Long term receivables from group companies 25,963 32,162 Financial assets 261,426 261,220 Inventory 68,497 86,655 Trade
Slide 14: Notes
Notes NOTE 1. ACCOUNTING POLICIES NOTE 3. RISKS AND UNCERTAINTIES The Group applies IFRS Accounting Standards, as adopted by the EU. This interim report has been CellaVision is exposed to several risks, which may impact the Group’s development to a greater prepared in accordance with IAS 34 Interim
Slide 15: Notes, Cont'd
Notes, Cont’d NOTE 5. INTANGIBLE ASSETS NOTE 7. FINANCIAL ASSETS AND LIABILITIES The disclosed value of financial assets, trade receivables, other receivables, cash and bank, trade Amounts in ‘ 000 SEK 12/31/2025 12/31/2024 payables, and other short-term liabilities constitutes a reasonable approxim
Slide 16: Reconciliation Tables KPIs, Non-IFRS Measures
Reconciliation Tables KPIs, Non-IFRS Measures Equity-asset ratio Amounts in ‘ 000 SEK 12/31/2025 12/31/2024 The company presents certain financial measures in the interim Equity 887,578 815,727 report which are not defined according to IFRS. The financial metrics are used by the company’s management
Slide 17: Questions Concerning the Report, Financial Calendar 2026
Questions Concerning the Report Publication This information constitutes information that CellaVision AB (publ) is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication on February 5, 2026 at 7:20 a.m. CET. CellaVision is listed on the Nasda
Slide 18: This is CellaVision
This is CellaVision Mission To advance laboratory workflow and diagnostic certainty through intelligent microscopy About Us Our Strategic Ambition: The Power of Focus CellaVision is an innovative, global medical technology company Our strategic ambition is to digitalize and improve microscopy Our to